Full-Time

Customer Master Data Management Senior Manager

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

Compensation Overview

$137.6k - $206.4k/yr

+ Annual bonus + Annual equity awards

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid

Hybrid work is available up to two remote days per week, or the role may be designated on-site five days per week.

Bachelor's

Category
Data & Analytics (1)
Required Skills
Veeva
ServiceNow
SQL
CRM
Salesforce
JIRA
Collibra
Data Governance
Oracle
HIPAA
Data Analysis
Snowflake

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Requirements
  • A Bachelor's Degree is required.
  • A minimum of 5 years of direct experience with pharmaceutical data sourcing, integration, analysis, and reporting is typically required.
  • Extensive knowledge of master data management processes and experience implementing and managing Informatica Master Data Management or other on-premises or cloud-based master data management solutions is required.
  • The candidate must be comfortable working with data, databases, and systems and communicate effectively with cross-functional stakeholders.
  • Familiarity with customer relationship management systems such as Veeva and Salesforce; databases and data warehouses such as Oracle and Snowflake; Structured Query Language; project planning; agile methodologies; JIRA; ServiceNow; performance metrics; and reporting is required.
  • Experience with data governance, data stewardship, and managing data vendors is required.
  • Understanding of legal and regulatory requirements related to sensitive protected health information, personally identifiable information, and compliance data, including HIPAA, GDPR, HITECH, and the Sunshine Act, is required.
  • The candidate must be able to clarify vaguely defined problems and apply a pragmatic approach to problem solving and service delivery.
  • A Bachelor's Degree is required.
  • Four to six years of relevant experience in a life sciences organization or healthcare industry with pharmaceutical data sourcing, integration, analysis, and reporting is typically required.
Responsibilities
  • Support the overall global customer mastering program.
  • Support the commercial data governance process in partnership with Information Technology and other stakeholders, including data cataloguing efforts with Collibra.
  • Work closely with a team of data stewards who execute data change requests and other data quality initiatives.
  • Support integrations with customer relationship management systems and other internal systems that depend on customer master data management.
  • Act as the data product owner for healthcare entity data within the company's customer relationship management systems.
  • Facilitate the loading of healthcare organization and healthcare professional data into master data management and downstream systems, including customer relationship management systems.
  • Work closely with the Data, Technology, and Engineering group to execute technology initiatives.
  • Coordinate the activities of vendor organizations that support master data management and customer relationship management.
  • Train internal teams on master data management-related processes and procedures.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex raised 2026 revenue guidance to $13.1-$13.2 billion after Q2 growth.
  • Povetacicept has a November 30, 2026 PDUFA date, opening nephrology revenue.
  • JOURNAVX hit $50 million in Q2 2026, while CASGEVY grew 151% year over year.

What critics are saying

  • Sionna axed SION-719 on August 10, 2026, but CF competition keeps advancing.
  • Zimislecel faced a voluntary manufacturing pause in 2026, exposing cell-therapy execution risk.
  • Crinetics adds $8.8 billion integration risk; a failed close leaves Vertex overdependent on CF.

What makes Vertex Pharmaceuticals unique

  • Vertex still owns CFTR modulators; Q2 2026 CF revenue reached $3.2 billion.
  • Vertex broadened beyond CF with CASGEVY, JOURNAVX, and Crinetics, announced July 2026.
  • Vertex moves fast: CASGEVY pediatric FDA approval arrived 53 days after filing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Ticker Report
Aug 19th, 2026
Wealthfront Advisers LLC Makes New $20.67 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX

Wealthfront Advisers LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,608 shares of the pharmaceutical company’s stock, valued at approximately $20,668,000. Other hedge funds also recently […]

Yahoo Finance
Aug 14th, 2026
Vertex Pharmaceuticals hits all-time high despite CF competition risks

Vertex Pharmaceuticals recently hit an all-time high after bouncing back from recent setbacks. The biotech continues dominating the cystic fibrosis (CF) market with no meaningful competition, generating $3.2 billion in CF revenue last quarter. Second-quarter sales reached $3.33 billion, up 12% year-over-year, whilst earnings per share rose 8% to $4.31. Several competitors have attempted to challenge Vertex's CF dominance, but most have failed. Sionna Therapeutics' leading CF candidate recently flopped in mid-stage trials, whilst AbbVie previously abandoned its CF programmes. Beyond CF, Vertex is expanding into new areas. The company expects $500 million in non-CF revenue by 2026. Its gene editing treatment Casgevy recently earned approval for children as young as two, whilst non-opioid pain medicine Journavx could gain additional indications.

Yahoo Finance
Aug 12th, 2026
Vertex Pharmaceuticals beats Q2 revenue estimates with $3.33B, driven by CF portfolio and newer products

Vertex Pharmaceuticals reported strong second-quarter results, with revenue of $3.33 billion beating analyst estimates of $3.19 billion. The company attributed growth to its cystic fibrosis portfolio and newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani highlighted that ALYFTREK and TRIKAFTA continued to drive CF revenue, whilst European launches benefitted from fewer monitoring requirements. The company raised its full-year revenue guidance to $13.15 billion at the midpoint from $13.03 billion. Adjusted earnings per share came in at $4.73, in line with analyst expectations of $4.75. Adjusted operating income reached $1.42 billion, exceeding estimates of $1.37 billion with a 42.7% margin. During the earnings call, analysts questioned management about Phase II/III study doses, payer dynamics for JOURNAVX, and clinical outcomes for next-generation CF therapies.

Yahoo Finance
Aug 11th, 2026
Vertex Q2 2026 revenue up 12% year-on-year, announces Crinetics acquisition

Vertex Pharmaceuticals reported strong second quarter 2026 results during its earnings call on 3 August. The company's total revenue grew 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. CEO Dr Reshma Kewalramani highlighted excellent performance across the company's commercial portfolio and research pipeline. Vertex also announced a definitive agreement to acquire Crinetics Pharmaceuticals, which will add rare endocrine diseases as a fifth therapeutic area alongside cystic fibrosis, sickle cell disease, beta-thalassemia, and pain management. The company emphasised 2026 as a year focused on execution across commercial, clinical, and regulatory fronts, with significant progress made during the quarter.

Yahoo Finance
Aug 7th, 2026
Sionna Therapeutics challenges Vertex Pharmaceuticals' $12B cystic fibrosis market dominance

Sionna Therapeutics is challenging Vertex Pharmaceuticals' dominance in the cystic fibrosis (CF) drug market. Vertex, valued at nearly $123 billion, generated $3.2 billion in CF-related sales in Q2, representing most of its $3.33 billion total revenue. Sionna, worth $2.2 billion, claims its approach could restore normal function to the CFTR protein, which causes CF when misfolded. Vertex's current treatments improve the protein's shape and function but don't restore normal function for most patients. Vertex generates over $12 billion annually from CF treatments. However, several companies, including AbbVie, have previously attempted to challenge Vertex's market position without success. Vertex has maintained its position since receiving its first CF drug approval in 2012.